ABRPL signs MoU with Malaysian Biotech

Mumbai, June 4 (UNI) Avesta Biotherapeutic and Research Pvt Ltd (ABRPL), a joint venture between Avesthagen and Meditab Specialities Ltd of Cipla Group, today signed a memorandum of understanding (MoU) with Malaysian Biotechnology Corporation for manufacture of biosimilar products.

In order to achieve early market access, the company has entered into the agreement to strengthen its infrastructure and accelerate 11 biosimilar product development programme, ABRPL said in a statement today.

Accordoing to the company, through this agreement, ABRPL would like to establish a legal presence in Malaysia and place the intellectual property rights for the products. This would further provide an opportunity for obtaining BioNexus status offered by the Government of Malaysia, it added.

UNI